Giant cell arteritis (GCA) and Takayasu’s arteritis (TA) are prototypes of large vessel vasculitis, tending to involve the aorta and its branches.
Giant cell arteritis predominantly affects the secondto fifth-order aortic branches, often in the extracranial arteries of the head.
Giant cell arteritis occurs exclusively among individuals who are 50 years of age or older. The mean age at diagnosis onset is approximately 72.
In TA, the aorta and its major branches are the prime disease targets.
Both GCA and TA are associated with granulomatous inflammation within the blood vessel wall.
In both GCA and TA, clinical symptoms of vascular inflammation and vascular insufficiency are usually accompanied or preceded by a systemic inflammatory process.
Visual loss is the most feared complication of GCA. Visual loss may occur through the syndrome of anterior ischemic optic neuropathy, caused by narrowing of the posterior ciliary artery and other vessels to the eye.
The diagnosis of GCA is made usually by biopsy of the temporal artery.
Polymyalgia rheumatica (PMR), a syndrome of muscle pain and stiffness in the neck, shoulders, and hips, often occurs with GCA but can occur independently.
■ Glucocorticoids are the cornerstone of treatment for GCA, TA, and PMR. Isolated PMR requires a lower dose of prednisone for disease control.
KeywordsMagnetic Resonance Angiography Giant Cell Arteritis Human Leukocyte Antigen Class Multinucleated Giant Cell Temporal Artery
Unable to display preview. Download preview PDF.
- 4.Weyand CM, Wagner AD, Bjornsson J, et al. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;987:1642–1649.Google Scholar
- 5.Rittner HL, Kaiser M, Brack A, et al. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999;849:1050–1058.Google Scholar
- 9.Kaiser M, Younge B, Bjornsson J, et al. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999;1553:765–774.Google Scholar
- 10.Rittner HL, Hafner V, Klimiuk PA, et al. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999;1037:1007–1013.Google Scholar
- 11.Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;1396:505–515.Google Scholar
- 13.Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a populationbased study over 50 years. Arthritis Rheum 2003;4812:3522–3531.CrossRefGoogle Scholar
- 14.Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;1227:502–507.Google Scholar
- 18.Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002;1374:232–238.Google Scholar
- 25.Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;1217:484–491.Google Scholar
- 27.Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997;1271:27–31.Google Scholar
- 28.Kerr GS. Takayasu’s arteritis. Rheum Dis Clin North Am 1995;214:1041–1058.Google Scholar
- 34.Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994;12011:919–929.Google Scholar